Chad Landmon chairs Axinn's Intellectual Property and Food and Drug Administration Practice Groups and focuses his practice on patent litigation and counseling and food and drug law, with an emphasis on pharmaceuticals, biologics, medical devices, and human tissue products. He maintains a particular focus on patent trial work, having served as a first chair trial lawyer on multiple cases and having litigated over 50 cases during the past 10 years alone, many of which have included products with billions of dollars in annual sales. He was recently selected as a National Law Journal Healthcare/Life Sciences Trailblazer, ranked by IAM Patent 1000: The World’s Leading Patent Professionals and named a 2019 Life Sciences Star by LMG Life Sciences for his exemplary work in combining patent litigation skills with the ability to maneuver through the complicated FDA regulatory regime.
Chad's FDA matters involve petitioning FDA and litigating issues relating to marketing exclusivities, patent listing, certification and notification requirements, bioequivalence, labeling, and other issues relevant to the FDA drug approval process. His active FDA litigation practice has enabled clients to maintain their marketing exclusivity rights and obtain market entry. In fact, Chad led the efforts to obtain a court order that has been described as the first time a court has ordered FDA to approve a product.
By coupling his patent litigation experience with his FDA expertise, Chad enables life sciences clients to develop and execute on patent and FDA strategies to bring products to market in the most efficient and profitable manner. In fact, during the course of his career, Chad has worked on eight of the top ten generic drugs ranked by cost savings and nearly half of the top 100 generic drugs by sales volume.
With a practice that also includes matters involving the intersection of the antitrust and patent laws, such as issues arising from the settlement of patent and Hatch-Waxman exclusivity disputes, Chad frequently speaks and writes about issues relating to the Hatch-Waxman Act, the Biologics Price Competition and Innovation Act, and litigation in the life sciences industry. He has served as a member of Law360's Life Sciences Editorial Advisory Board since 2018. In addition, Chad is an active member in various professional committees, including the Food and Drug Law Institute’s Medical Products Committee and the Association for Accessible Medicines’ Biosimilars Council.